QNRX News and Press, Quoin Pharmaceuticals Ltd. From 03/15/22

Quoin Pharmaceuticals (NASDAQ:QNRX) submitted an investigational new drug application to the U.S. Food and Drug Administration to begin clinical trial of topical lotion QRX003 for Netherton Syndrome (NS). NS is a rare genetic disorder characterized by scaling skin, hair anomalies and inc...

ASHBURN, Va., March 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals,...

Clearside Biomedical (NASDAQ:CLSD) +30% on Q4 results. Pearson (NYSE:PSO) +21% on report Apollo considering making offer for education company. Lazydays Holdings (NASDAQ:LAZY) +19%. 4D pharma (NASDAQ:LBPS) +18%. Superior Drilling Products (NYSE:SDPI) +16% on Q4 r...

ASHBURN, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals,...

Quoin Pharmaceuticals (QNRX +0.9%) extended its exclusive distribution agreement with ER-Kim to six additional countries for QRX003, to treat Netherton Syndrome. Under the terms of the revenue sharing agreement, which was initially announced in February, ER-Kim (a partner for b...

ER-Kim Gains Exclusive Rights to Commercialize QRX003 to Six Additional Countries 60 Countries Now Covered by Partnership Agreements for QRX003 ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or ...

Neopharm Gains Exclusive Rights to Commercialize QRX003 in Israel Sixth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company&#...

Quoin Pharmaceuticals (NASDAQ:QNRX) signed an exclusive distribution agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe (CCE), for the company's investigational treatment QRX003 for Netherton syndrome, Under the agreement, ER-Kim gains exclusive rig...

- ER-Kim Gains Exclusive Rights to Commercialize QRX003 Across Central & Eastern Europe - Fifth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX...

New York, NY - ( NewMediaWire ) - February 08, 2022 -  PCG Digital  - Emerging specialty pharma company, Quoin Pharmaceuticals (NASDAQ: QNRX), coined the phrase ‘Rare diseases are only rare if you don’t live with one’ to emphasize its own mission: to del...